-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Author: cockle
On March 26, Bristol-Myers Squibb and bluebird jointly announced that the FDA has approved Abecma (idecabtagenevicleucel; ide-cel) as the first targeted chimeric antigen receptor (CAR) T cell immunity targeting B cell maturation antigen (BCMA) Therapies are used to treat adult patients with relapsed or refractory multiple myeloma.
Multiple myeloma (MM) is a malignant disease in which clonal plasma cells proliferate abnormally.
BCMA is an extremely important B cell biomarker, which is widely present on the surface of MM cells.
The FDA approval is based on data from a key Phase II clinical study code-named KarMMa.
The results of the study showed that the overall response rate (ORR) of 100 patients with evaluable efficacy was 72% (95% CI: 62-81), and 28% of patients achieved strict complete remission (sCR, 95% CI: 19%-38) %).
Note: The original text has been deleted